Gambacorti-Passerini C - Search Results

1

Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.

Redaelli S, Ceccon M, Zappa M, Sharma GG, Mastini C, Mauri M, Nigoghossian M, Massimino L, Cordani N, Farina F, Piazza R, Gambacorti-Passerini C, Mologni L. Redaelli S, et al. Cancer Res. 2018 Dec 15;78(24):6866-6880. doi: 10.1158/0008-5472.CAN-18-1867. Epub 2018 Oct 15. Cancer Res. 2018. PMID: 30322862

2

Additive antisense effects of different PNAs on the in vitro translation of the PML/RARalpha gene.

Mologni L, leCoutre P, Nielsen PE, Gambacorti-Passerini C. Mologni L, et al. Nucleic Acids Res. 1998 Apr 15;26(8):1934-8. doi: 10.1093/nar/26.8.1934. Nucleic Acids Res. 1998. PMID: 9518485 Free PMC article.

3

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.

le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti-Passerini C. le Coutre P, et al. J Natl Cancer Inst. 1999 Jan 20;91(2):163-8. doi: 10.1093/jnci/91.2.163. J Natl Cancer Inst. 1999. PMID: 9923858

4

In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acid.

Mologni L, Nielsen PE, Gambacorti-Passerini C. Mologni L, et al. Biochem Biophys Res Commun. 1999 Oct 22;264(2):537-43. doi: 10.1006/bbrc.1999.1548. Biochem Biophys Res Commun. 1999. PMID: 10529398

5

Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.

le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, Gambacorti-Passerini C. le Coutre P, et al. Blood. 2000 Mar 1;95(5):1758-66. Blood. 2000. PMID: 10688835 Free article.

6

Inhibition of promyelocytic leukemia (PML)/retinoic acid receptor-alpha and PML expression in acute promyelocytic leukemia cells by anti-PML peptide nucleic acid.

Mologni L, Marchesi E, Nielsen PE, Gambacorti-Passerini C. Mologni L, et al. Cancer Res. 2001 Jul 15;61(14):5468-73. Cancer Res. 2001. PMID: 11454693

7

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Gambacorti-Passerini CB, et al. Lancet Oncol. 2003 Feb;4(2):75-85. doi: 10.1016/s1470-2045(03)00979-3. Lancet Oncol. 2003. PMID: 12573349 Review.

8

Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels.

Gambacorti-Passerini C, Piazza R, D'Incalci M. Gambacorti-Passerini C, et al. Blood. 2003 Sep 1;102(5):1933-4; author reply 1934-5. doi: 10.1182/blood-2003-05-1629. Blood. 2003. PMID: 12930735 Free article. No abstract available.

9

Development of c-Kit-expressing small-cell lung cancer in a chronic myeloid leukemia patient during imatinib treatment.

Gambacorti-Passerini C, Piazza R, Tornaghi L, Pilotti S, Pogliani E. Gambacorti-Passerini C, et al. J Natl Cancer Inst. 2004 Nov 17;96(22):1723-4. doi: 10.1093/jnci/djh330. J Natl Cancer Inst. 2004. PMID: 15547187 No abstract available.

10

Expression, purification, and inhibition of human RET tyrosine kinase.

Mologni L, Sala E, Riva B, Cesaro L, Cazzaniga S, Redaelli S, Marin O, Pasquato N, Donella-Deana A, Gambacorti-Passerini C. Mologni L, et al. Protein Expr Purif. 2005 May;41(1):177-85. doi: 10.1016/j.pep.2005.01.002. Protein Expr Purif. 2005. PMID: 15802236

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

376 results

Search Page

Filters